Ubs Asset Management Americas Inc Adverum Biotechnologies, Inc. Transaction History

Ubs Asset Management Americas Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	BUY	$2.08 - $3.6 $75,112 - $130,003	36,112 Added 26.19%	173,979 $377,000
Q2 2021 Aug 16, 2021	SELL	$3.36 - $10.56 $1.49 Million - $4.68 Million	-443,405 Reduced 76.28%	137,867 $482,000
Q1 2021 May 14, 2021	BUY	$9.26 - $14.36 $13,547 - $21,008	1,463 Added 0.25%	581,272 $5.73 Million
Q4 2020 Mar 01, 2021	SELL	$9.84 - $14.26 $2.57 Million - $3.72 Million	-260,695 Reduced 31.02%	579,809 $6.29 Million
Q3 2020 Nov 13, 2020	BUY	$10.3 - $21.64 $731,258 - $1.54 Million	70,996 Added 9.23%	840,504 $8.66 Million
Q2 2020 Aug 14, 2020	BUY	$8.53 - $25.64 $127,907 - $384,471	14,995 Added 1.99%	769,508 $16.1 Million
Q1 2020 May 15, 2020	BUY	$7.98 - $16.32 $3.92 Million - $8.01 Million	490,615 Added 185.91%	754,513 $7.37 Million
Q4 2019 Feb 14, 2020	BUY	$5.12 - $12.22 $1.35 Million - $3.22 Million	263,898 New	263,898 $3.04 Million

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.